Published in Antimicrob Agents Chemother on April 02, 2012
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.10
Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One (2014) 1.07
Tumor necrosis factor neutralization combined with chemotherapy enhances Mycobacterium tuberculosis clearance and reduces lung pathology. Am J Clin Exp Immunol (2013) 0.85
Advances in Drug Discovery and Development for Pediatric Tuberculosis. Mini Rev Med Chem (2016) 0.82
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrob Agents Chemother (2013) 0.78
Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms. Exp Ther Med (2015) 0.77
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. Antimicrob Agents Chemother (2015) 0.75
The search for synergy: a critical review from a response surface perspective. Pharmacol Rev (1995) 8.24
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 3.76
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother (2007) 2.58
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2006) 2.14
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother (2007) 1.26
Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother (2005) 1.09
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother (2007) 1.09
Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin. J Antimicrob Chemother (2008) 1.05
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 3.76
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med (1992) 3.34
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother (2008) 3.09
Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs (1999) 2.83
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother (1998) 2.59
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother (1994) 2.46
Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 2.44
Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 2.43
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2001) 2.24
Expression of conjoined genes: another mechanism for gene regulation in eukaryotes. PLoS One (2010) 2.13
Nonalcoholic fatty liver is not associated with incident chronic kidney disease: a large histology-based comparison with healthy individuals. Eur J Gastroenterol Hepatol (2016) 2.06
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS (1996) 2.03
Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother (1984) 1.98
Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.97
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother (1999) 1.90
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother (2011) 1.75
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother (1998) 1.73
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis (2007) 1.70
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob Agents Chemother (2005) 1.69
Relative affinities of all Escherichia coli aminoacyl-tRNAs for elongation factor Tu-GTP. J Biol Chem (1984) 1.62
Prevalence of sustained hypertension and obesity in urban and rural school going children in Ludhiana. Indian Heart J (2004) 1.57
The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis (1984) 1.48
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother (1985) 1.46
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob Agents Chemother (2011) 1.46
Complete genome sequences of rat and mouse segmented filamentous bacteria, a potent inducer of th17 cell differentiation. Cell Host Microbe (2011) 1.46
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am (1997) 1.45
Fluoroquinolone pharmacodynamics. Clin Infect Dis (2001) 1.45
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. J Infect Dis (1995) 1.43
Influenza A/H1/N1/09 infection in patients with cirrhosis has a poor outcome: a case series. Indian J Gastroenterol (2014) 1.42
Kinetic studies of Escherichia coli elongation factor Tu-guanosine 5'-triphosphate-aminoacyl-tRNA complexes. Biochemistry (1985) 1.41
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother (2011) 1.35
Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison. Rev Infect Dis (1984) 1.33
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2007) 1.33
Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agents Chemother (1984) 1.31
An overview of the pharmacology of imipenem/cilastatin. J Antimicrob Chemother (1986) 1.31
Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci U S A (1993) 1.29
Influence of zinc on Pseudomonas aeruginosa susceptibilities to imipenem. J Clin Microbiol (1993) 1.28
A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections. Surg Gynecol Obstet (1982) 1.28
Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med (1985) 1.28
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother (2010) 1.27
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther (1990) 1.25
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother (2005) 1.24
Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. J Biol Chem (1993) 1.24
Immunohistochemical, electron microscopic and in situ hybridization evidence for the involvement of lymphatics in the spread of HIV-1. AIDS (1988) 1.24
Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.23
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother (1998) 1.23
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect (2009) 1.22
Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1987) 1.22
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother (1999) 1.21
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1993) 1.21
Conditional expression of a Gi-coupled receptor in osteoblasts results in trabecular osteopenia. Endocrinology (2007) 1.20
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1995) 1.20
Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J Virol (2009) 1.19
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother (1986) 1.18
Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother (2013) 1.18
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother (1987) 1.17
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrob Agents Chemother (2009) 1.16
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother (2008) 1.14
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol (1993) 1.14
Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia. Antimicrob Agents Chemother (2011) 1.13
In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 1.10
Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother (2009) 1.10
Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis (2009) 1.10
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol (1984) 1.08
T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci U S A (2011) 1.07
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother (2009) 1.07
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother (1999) 1.06
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother (2009) 1.05
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J (2009) 1.03
Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli. Antimicrob Agents Chemother (1981) 1.03
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens. Antimicrob Agents Chemother (1987) 1.03
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates. Antimicrob Agents Chemother (1998) 1.03
Optimal sampling schedule design for populations of patients. Antimicrob Agents Chemother (2003) 1.03
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother (2010) 1.03
Fast and accurate taxonomic assignments of metagenomic sequences using MetaBin. PLoS One (2012) 1.02
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents. Antimicrob Agents Chemother (1985) 1.02
Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit Care Clin (2011) 1.02
Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. Antimicrob Agents Chemother (2011) 1.02
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother (2006) 1.01
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother (1999) 1.01
Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother (1994) 1.00
Multiple-dose ciprofloxacin dose ranging and kinetics. Clin Pharmacol Ther (1985) 1.00
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother (2012) 1.00
Cefoxitin falsely elevates creatinine levels. JAMA (1982) 1.00
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother (1989) 1.00
Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. J Clin Microbiol (1998) 1.00
Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res (2004) 1.00
Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers. Rev Infect Dis (1983) 1.00
Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin. Antimicrob Agents Chemother (1984) 0.99